news
Key insights into vaccine development for herpesviruses
Researchers found that the D48 antibody neutralised HSV-1 virus infection, which could lead to broad-spectrum drug and vaccine development.
List view / Grid view
Antibodies
news
Developing an effective vaccine for herpes simplex virus
Researchers have identified key differences between HSV-1 and HSV-2 and have developed monoclonal antibodies that could treat neonatal infections.
article
eBook: Reveal Cell Function With Single-Cell Resolution
This eBook explores a new means to perform single-cell functional analysis. Uncover the Xdrop®single-cell format workflow with its ability to help identify, quantify, and comprehend immune cell functions at the individual cellular level.
whitepaper
Application Note: Understanding The Multiplex Imaging Landscape
Learn about the different types of multiplexed imaging available, as well as their applications, benefits and disadvantages.
whitepaper
Application note: In situ identification of cancer stem cell niches (HCC)
This app note explores a groundbreaking multiplex immunodetection approach to identify cancer stem cell niches within hepatocellular carcinoma (HCC).
article
The promise of 3A5C7 mAb in the treatment of morphine tolerance
Morphine is a frequently used analgesic that activates the mu-opioid receptor (MOR), which has prominent side effects of tolerance. A monoclonal antibody (mAb) precisely targeting MOR, named as 3A5C7, was developed to treat morphine tolerance by enhancing morphine-induced MOR endocytosis via GRK2/β-arrestin2 pathway. In this Q&A session with Dr Jia-Jia…
news
New immunological pathway to treat bone tumours
Researchers observed significant upregulation of Siglec-15 in the tumour microenvironment in bone tumour samples from breast cancer patients.
news
Knockdown of FAM3C inhibits breast cancer tumour growth
Inhibition of FAM3C expression in cancer-associated adipocytes during early tumour development holds promise as a novel treatment approach.
webinar
Developing next generation non-replicative HSV-1 vectors for sustainable and more precise gene therapies
22 January 2024 | By Drug Target Review, sponsored by Bio Rad Technologies
Watch this webinar to learn how the challenges with using certain viral vectors in gene therapy has advanced the development of a new generation of precise vectors with sustainable effects. Our experts outline the limitations of existing vectors and how these can be overcome using modified recombinant non-replicative herpes simplex…
whitepaper
Case Study: Target discovery for rheumatoid arthritis
Learn more about Euretos computational disease model and how it predicts many of the known drug targets for RA.
news
Nasal administration of IgA antibodies protects from SARS-CoV-2
Genetic engineering created IgA antibodies that bind to the SARS-CoV-2 spike protein in a similar way to IgG antibodies.
whitepaper
Article: Tips and Tricks for Leveraging Advanced Flow Cytometry
Tips and tricks for fully leveraging Advanced Flow Cytometry.
whitepaper
Application note: Direct and Competitive Live Cell Antibody Binding
Utilizing Advanced High-Throughput Flow Cytometry to Quantify Direct and Competitive Live Cell Antibody Binding
news
Advancing the development of CTLA-4 inhibitors
A new study could result in CTLA-4 inhibitors that promote antitumour responses without causing intestinal diseases, such as colitis.
news
Delivering a human monoclonal IgG1 antibody to the brain
Adding a biodegradable polymer at the hinge and near hinge regions of trastuzumab enabled its movement across the blood-brain barrier.